Comparison of Optokinetic Stimulation Treatments

Peripheral Vestibular Disorder Clinical Trial

Official title:

The Effect of Virtual Reality and DVD Optokinetic Stimulation Exposure on Visual Induced Dizziness Symptoms in Persons With a Vestibular Disorder

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04649268
• Other study ID #: REC Reference: 20/LO/1244
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 28, 2021
• Est. completion date: June 30, 2022

Study information

• Verified date: November 2020
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Persons with a vestibular (e.g. inner ear) disorder often report visual induced dizziness (ViD) symptom (i.e. postural and/or gait instability, dizziness, disorientation) provocation or exacerbation in environments with busy or conflicting visual motion including crowds and supermarkets. ViD is frequently associated with high disability levels, prolonged illness and poorer clinical outcome. Thus, effective treatment is a priority. Vestibular rehabilitation incorporating structured exposure to Optokinetic Stimulation (OKS) (e.g. a form of computer based intervention that involves the observation of moving visual targets to encourage visual scanning) significantly improves ViD symptoms with similar improvement noted for both 'low-tech' OKS provided via a DVD or a 'high-tech', expensive, full-field stimulus. No studies have investigated if 'lower-tech', cheaper Virtual Reality (VR) systems may be beneficial in treating ViD symptoms and whether these VR systems are more effective than an OKS DVD. The first aim of this work is to compare the effect of an OKS DVD vs "lower-tech" VR system on ViD symptoms in persons with a chronic peripheral vestibular disorder aged 18-50 years old. This study may help to identify more optimal treatment strategies in persons with a vestibular disorder.

Description:

Background People with ViD report symptom (i.e. postural and/or gait instability, dizziness, disorientation) provocation or exacerbation in environments with busy or conflicting visual motion including crowds, supermarkets and scrolling computer screens. Visual dependence and impaired sensory re-weighting have been identified as main contributors to balance problems in persons with vestibular disorders and are frequently associated with high disability levels, prolonged illness, and poorer clinical outcome in adults with vestibular dysfunction including vestibular migraine. Evidence suggests that ViD symptoms respond well to rehabilitation incorporating structured exposure to OKS. Treatment with gradual, progressive exposure to OKS in combination with static and dynamic functional balance exercises has been shown to improve visual dependency, functional balance and gait as well as symptoms provoked or exacerbated in busy visual environments, such as crowds, in persons with a vestibular disorder. It is believed that improvements in ViD following treatment with OKS is due to sensory-reweighting which is the ability of CNS to adapt its relative reliance on a specific sensory modality for purposes of orientation depending on environmental conditions, task demands and/ or pathology. During neuroimaging studies, exposure to visual OKS, in the absence of vestibular stimulation, results in consistent activation of cortical regions involved in the control of visual motion processing and eye movement, and deactivation of parieto-insular vestibular cortices indicating a reciprocally inhibitory visual-vestibular interaction. Similarly, stimulation of multisensory vestibular cortex areas results in bilateral deactivation in visual and somatosensory cortex areas. These interactions may have a functional significance and indicate a sensor re-weighting process with greater weight given to the more reliable input thus suppressing the possible mismatch between contrasting sensory information. It is believed that the recurring exposure to conflicting visual input promotes reduced visual reliance and facilitates a more effective use of vestibule-proprioceptive cues through sensory re-weighting. However, the exact mechanisms involved in sensory re-weighting in persons with visual induced dizziness remain poorly understood. Finally, previous work has demonstrated that low tech OKS provided via a DVD produces the same level of improvement as a more expensive, full field stimulus. Findings for the effect of virtual reality (VR) on ViD are inconclusive. Furthermore, to date only VR provided via an immersive projection theatre, often referred to as a CAVE has been used to investigate its effect on ViD. This equipment is very expensive and available only within a specialist centre. No studies have investigated if 'lower-tech' VR such as VR headset and specifically, Oculus Quest headset, may be beneficial in treatment of ViD at a much lower cost. The use of 'lower-tech' OKS equipment is promising, more widely available to clinical practice and safe to be used at home by the patients for rehabilitation purposes. However, it is not known if one type of 'lower-tech' equipment may provide greater benefit compared to another. Purpose of the study The proposed pilot study is a non-commercial-PhD student project. The purpose of this investigation is to compare two types of OKS based VRT for the improvement of ViD in persons with a chronic vestibular disorder. Objectives/Aims of the study The primary objective of this study is to compare the effect of two types of optokinetic stimulation (OKS) based vestibular rehabilitation (VRT) programmes on Situational Characteristics Questionnaire (SCQ) scores in persons with a chronic vestibular disorder who experience ViD aged 18-50 years old. The secondary objectives are to compare the pre-post treatment effect of two types of OKS based VRT on subjective dizziness, psychological state, balance confidence and objective gait, balance and ViD symptoms. Primary Hypothesis Both types of OKS will provide significant improvement on SCQ scores, but improvement with VR will be greater. Secondary Hypothesis VRT with VR Oculus Quest headset may provide greater treatment outcome on gait and balance control, participant's subjective symptoms, psychological state and cognitive function.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: June 30, 2022
• Est. primary completion date: December 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. clinical diagnosis of a peripheral vestibular disorder;

2. chronic dizziness and/or unsteadiness;

3. 18 to 50 years old;

4. no previous rehabilitation or previous VRT programme completed with partial/no improvement;

5. willing to participate and to comply with the proposed training and testing regime; and

6. current SCQ score >0,7/4. Patient diagnosis will be based on clinical history and/or neuro-otological findings, according to published normative data and limits. Persons with Benign Paroxysmal Positional Vertigo (BPPV) will be included, in the study, due to the persistence of imbalance and dizziness after BPPV resolution. The diagnosis of migraine will be made according to the International Headache Society Criteria for Migraine as well as Neuhauser Criteria for VM. Exclusion Criteria:

Persons with:

1. central nervous system involvement, excluding migraine. However, patients with severe migraine (> 3 migrainous headaches monthly) will be excluded.

2. fluctuating symptoms, for example, active Ménière disease;

3. acute orthopaedic disorders influencing balance control and gait;

4. a score of < 23/30 on the MoCA;

5. a score of >15/21 on the HADS for the depression component indicating significant depression symptoms;

6. inability to attend sessions;

7. diagnosis of neurological disorder;

8. currently attending or has completed a rehabilitation programme targeting balance and/or dizziness in the past year or is currently part of a clinical trial testing a medicinal product. These factors may skew both the assessment scores and treatment outcome and for this reason they are listed as exclusion criteria; and

9. lack of a good grasp of written/spoken English will be excluded. The latter due to the need to complete multiple questionnaires and the lack of funding for interpreters.

Related Conditions & MeSH terms

• Ear Diseases
• Peripheral Vestibular Disorder
• Vestibular Diseases

Intervention

Device:
• Group B
The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.

Other:
• Group A
Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.

Locations

Country	Name	City	State
United Kingdom	King's College London	London

Sponsors (2)

Lead Sponsor	Collaborator
King's College London	University College, London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (48)

15. D.S.C. Cruz-Neira & T. DeFanti, Surround-screen projection-based virtual reality: Design and implementation of the CAVE, in: Proceedings of SIGGRAPH, 1993; 135-142.

Aminian K, Najafi B, Büla C, Leyvraz PF, Robert P. Spatio-temporal parameters of gait measured by an ambulatory system using miniature gyroscopes. J Biomech. 2002 May;35(5):689-99. — View Citation

Bisdorff A, Von Brevern M, Lempert T, Newman-Toker DE. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res. 2009;19(1-2):1-13. doi: 10.3233/VES-2009-0343. — View Citation

Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. Review. — View Citation

Brandt T, Bartenstein P, Janek A, Dieterich M. Reciprocal inhibitory visual-vestibular interaction. Visual motion stimulation deactivates the parieto-insular vestibular cortex. Brain. 1998 Sep;121 ( Pt 9):1749-58. — View Citation

Cambridge-Cognition-Limited. CANTABeclipse™: Test Administration Guide Manual. 3rd ed. Cambridge 2015.

Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry. 2018 Feb;33(2):379-388. doi: 10.1002/gps.4756. Epub 2017 Jul 21. — View Citation

Cawthorne TE. The physiological basis for head exercises. J Chart Soc Physiother. 1944; 30:106-107.

Cousins S, Cutfield NJ, Kaski D, Palla A, Seemungal BM, Golding JF, Staab JP, Bronstein AM. Visual dependency and dizziness after vestibular neuritis. PLoS One. 2014 Sep 18;9(9):e105426. doi: 10.1371/journal.pone.0105426. eCollection 2014. — View Citation

Davies RA, Luxon LM. Dizziness following head injury: a neuro-otological study. J Neurol. 1995 Mar;242(4):222-30. — View Citation

Dichgans J, Held R, Young LR, Brandt T. Moving visual scenes influence the apparent direction of gravity. Science. 1972 Dec 15;178(4066):1217-9. — View Citation

Dieterich M, Bense S, Stephan T, Yousry TA, Brandt T. fMRI signal increases and decreases in cortical areas during small-field optokinetic stimulation and central fixation. Exp Brain Res. 2003 Jan;148(1):117-27. Epub 2002 Nov 13. — View Citation

Egerházi A, Berecz R, Bartók E, Degrell I. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):746-51. Epub 2007 Jan 16. — View Citation

Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ. Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc. 2002 Jan;8(1):58-71. — View Citation

Guerraz M, Yardley L, Bertholon P, Pollak L, Rudge P, Gresty MA, Bronstein AM. Visual vertigo: symptom assessment, spatial orientation and postural control. Brain. 2001 Aug;124(Pt 8):1646-56. — View Citation

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. — View Citation

Indovina I, Riccelli R, Chiarella G, Petrolo C, Augimeri A, Giofrè L, Lacquaniti F, Staab JP, Passamonti L. Role of the Insula and Vestibular System in Patients with Chronic Subjective Dizziness: An fMRI Study Using Sound-Evoked Vestibular Stimulation. Fr — View Citation

Julious SA. Sample size of 12 per group rule of thumb for a pilot study. In. Vol 4: J Pharmaceutical Statistics 2005; (4): 287-291.

Kleinschmidt A, Thilo KV, Büchel C, Gresty MA, Bronstein AM, Frackowiak RS. Neural correlates of visual-motion perception as object- or self-motion. Neuroimage. 2002 Aug;16(4):873-82. — View Citation

Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, Bisdorff A, Versino M, Evers S, Newman-Toker D. Vestibular migraine: diagnostic criteria. J Vestib Res. 2012;22(4):167-72. doi: 10.3233/VES-2012-0453. — View Citation

Lempert T. Vestibular migraine. Semin Neurol. 2013 Jul;33(3):212-8. doi: 10.1055/s-0033-1354596. Epub 2013 Sep 21. Review. — View Citation

Marchetti GF, Lin CC, Alghadir A, Whitney SL. Responsiveness and minimal detectable change of the dynamic gait index and functional gait index in persons with balance and vestibular disorders. J Neurol Phys Ther. 2014 Apr;38(2):119-24. doi: 10.1097/NPT.00 — View Citation

Micarelli A, Viziano A, Micarelli B, Augimeri I, Alessandrini M. Vestibular rehabilitation in older adults with and without mild cognitive impairment: Effects of virtual reality using a head-mounted display. Arch Gerontol Geriatr. 2019 Jul - Aug;83:246-25 — View Citation

Mohler MJ, Wendel CS, Taylor-Piliae RE, Toosizadeh N, Najafi B. Motor Performance and Physical Activity as Predictors of Prospective Falls in Community-Dwelling Older Adults by Frailty Level: Application of Wearable Technology. Gerontology. 2016;62(6):654 — View Citation

Morozetti PG, Ganança CF, Chiari BM. Comparison of different protocols for vestibular rehabilitation in patients with peripheral vestibular disorders. J Soc Bras Fonoaudiol. 2011 Mar;23(1):44-50. English, Portuguese. — View Citation

Muchna A, Najafi B, Wendel CS, Schwenk M, Armstrong DG, Mohler J. Foot Problems in Older Adults (Associations with Incident Falls, Frailty Syndrome, and Sensor-Derived Gait, Balance, and Physical Activity Measures). J Am Podiatr Med Assoc. 2018 Mar;108(2) — View Citation

Najafi B, Helbostad JL, Moe-Nilssen R, Zijlstra W, Aminian K. Does walking strategy in older people change as a function of walking distance? Gait Posture. 2009 Feb;29(2):261-6. doi: 10.1016/j.gaitpost.2008.09.002. Epub 2008 Oct 25. — View Citation

Najafi B, Horn D, Marclay S, Crews RT, Wu S, Wrobel JS. Assessing postural control and postural control strategy in diabetes patients using innovative and wearable technology. J Diabetes Sci Technol. 2010 Jul 1;4(4):780-91. — View Citation

Najafi B, Lee-Eng J, Wrobel JS, Goebel R. Estimation of Center of Mass Trajectory using Wearable Sensors during Golf Swing. J Sports Sci Med. 2015 May 8;14(2):354-63. eCollection 2015 Jun. — View Citation

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am — View Citation

Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. Neurology. 2001 Feb 27;56(4):436-41. — View Citation

Oculus Quest Review: Facebook's VR Savior Mostly Keeps its Promises. UploadVR 2019-05-22. Retrieved 2019-06-02.

Park JH, Jeon HJ, Lim EC, Koo JW, Lee HJ, Kim HJ, Lee JS, Song CG, Hong SK. Feasibility of Eye Tracking Assisted Vestibular Rehabilitation Strategy Using Immersive Virtual Reality. Clin Exp Otorhinolaryngol. 2019 Nov;12(4):376-384. doi: 10.21053/ceo.2018. — View Citation

Pavlou M, Bronstein AM, Davies RA. Randomized trial of supervised versus unsupervised optokinetic exercise in persons with peripheral vestibular disorders. Neurorehabil Neural Repair. 2013 Mar-Apr;27(3):208-18. doi: 10.1177/1545968312461715. Epub 2012 Oct — View Citation

Pavlou M, Davies RA, Bronstein AM. The assessment of increased sensitivity to visual stimuli in patients with chronic dizziness. J Vestib Res. 2006;16(4-5):223-31. — View Citation

Pavlou M, Kanegaonkar RG, Swapp D, Bamiou DE, Slater M, Luxon LM. The effect of virtual reality on visual vertigo symptoms in patients with peripheral vestibular dysfunction: a pilot study. J Vestib Res. 2012;22(5-6):273-81. doi: 10.3233/VES-120462. — View Citation

Pavlou M, Lingeswaran A, Davies RA, Gresty MA, Bronstein AM. Simulator based rehabilitation in refractory dizziness. J Neurol. 2004 Aug;251(8):983-95. — View Citation

Pavlou M, Quinn C, Murray K, Spyridakou C, Faldon M, Bronstein AM. The effect of repeated visual motion stimuli on visual dependence and postural control in normal subjects. Gait Posture. 2011 Jan;33(1):113-8. doi: 10.1016/j.gaitpost.2010.10.085. Epub 201 — View Citation

Shumway-Cook A, Horak FB. Rehabilitation strategies for patients with vestibular deficits. Neurol Clin. 1990 May;8(2):441-57. Review. — View Citation

Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012 Mar;65(3):301-8. doi: 10.1016/j.jclinepi.2011.07.011. Epub 2011 Dec 9. — View Citation

Thiede R, Toosizadeh N, Mills JL, Zaky M, Mohler J, Najafi B. Gait and balance assessments as early indicators of frailty in patients with known peripheral artery disease. Clin Biomech (Bristol, Avon). 2016 Feb;32:1-7. doi: 10.1016/j.clinbiomech.2015.12.0 — View Citation

Van Ombergen A, Heine L, Jillings S, Roberts RE, Jeurissen B, Van Rompaey V, Mucci V, Vanhecke S, Sijbers J, Vanhevel F, Sunaert S, Bahri MA, Parizel PM, Van de Heyning PH, Laureys S, Wuyts FL. Altered functional brain connectivity in patients with visual — View Citation

Viziano A, Micarelli A, Augimeri I, Micarelli D, Alessandrini M. Long-term effects of vestibular rehabilitation and head-mounted gaming task procedure in unilateral vestibular hypofunction: a 12-month follow-up of a randomized controlled trial. Clin Rehab — View Citation

Whitney SL, Wrisley DM, Brown KE, Furman JM. Physical therapy for migraine-related vestibulopathy and vestibular dysfunction with history of migraine. Laryngoscope. 2000 Sep;110(9):1528-34. — View Citation

Wrisley DM, Kumar NA. Functional gait assessment: concurrent, discriminative, and predictive validity in community-dwelling older adults. Phys Ther. 2010 May;90(5):761-73. doi: 10.2522/ptj.20090069. Epub 2010 Apr 1. — View Citation

Wrisley DM, Marchetti GF, Kuharsky DK, Whitney SL. Reliability, internal consistency, and validity of data obtained with the functional gait assessment. Phys Ther. 2004 Oct;84(10):906-18. — View Citation

Yardley L, Masson E, Verschuur C, Haacke N, Luxon L. Symptoms, anxiety and handicap in dizzy patients: development of the vertigo symptom scale. J Psychosom Res. 1992 Dec;36(8):731-41. — View Citation

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. — View Citation

* Note: There are 48 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Situational Characteristics Questionnaire (SCQ)	This is the primary outcome. The Situational Characteristics Questionnaire (SCQ) -shortened version measures how frequently symptoms are provoked or exacerbated in environments with visual vestibular mismatch or intense visual motion (e.g. travelling on escalators, crowds, scrolling computer screens). Scores =0.7/4 indicate visual induced dizziness symptoms.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	Functional Gait Assessment (FGA)	It is a 10-item test that assesses performance on complex gait tasks (i.e. walking with head turns, stepping over an obstacle or stopping and turning). The highest score is 30 and greater outcomes are indicative of better performance. The FGA has been validated in healthy people, older adults with a history of falls and balance impairments, and people with a vestibular disorder. The minimal detectable change for the FGA is reported to be 6 points in persons with balance and vestibular disorders. Scores =22/30 identify fall risk and are predictable of falls in community-living older persons within 6 months.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	Cambridge Neuropsychological Test Automated Battery (CANTAB)	Cambridge Neuropsychological Test Automated Battery (CANTAB) is a semi-automated computer program that utilizes a touch screen technology and press pad, to assess neurocognitive function. The CANTAB core cognition battery is a validated cognitive assessment system for assessing multiple components of cognitive function, including attention, visual memory, spatial memory, executive function and reaction time.; Each subject will be comfortably seated at approximate distance of 0.5m away from the screen pad monitor and will be asked to complete the CANTAB tests after instructions have been provided. The tests that will be included are Rapid Visual Information Processing (RVP), Paired Associates Learning (PAL), Spatial Working Memory (SWM), Reaction Time (RTI), Delayed Matching to Sample (DMS), Motor Screening Task (MOT), Spatial Span (SSP) and Multitasking Test (MTT). The test order will be different for each participant.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	Rod and Disc Test	Visual dependence is measured using the Rod and Disk Test on a laptop computer. Participants will be seated in front of a computer in a darkened room with their head held against a viewing cone that blocks extraneous visual orientation cues. The diameter of the cone at the participants' eyes will be 15cm with a depth of field of 30 cm, subtending a viewing angle of 39 degrees. The visual stimulus consists of a luminous white 6cm rod on a black background. The rod rotated 360 degrees in either direction about its midpoint in the central 11 degrees of the visual filed. Outside of this central zone, the viewing screen is filled with a collage of 220 off-white dots, each 8mm (1.5 degrees of visual field) in diameter, randomly distributed on a black background. Participants control the orientation of the rod with a roller mouse. They are instructed to align the rod to their perceived vertical (the subjective visual vertical) under three conditions.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	LEGSys™ and Balansens (Biosensics, MA, USA)	LEGSys™and Balansens (Biosensics, MA, USA) which will be used to assess gait and balance respectively, are a validated wearable technology that uses five inertial sensors (triaxial accelerometer and gyroscope) attached to both shins above ankles, thighs above knees, and lower back close to sacrum.; Balance will be measured in four trials of 15 seconds, (1) with eyes open on a stable surface with no visual target specified, (2) with eyes closed on a stable surface, (3) with eyes closed on an incline surface and (4) with eyes closed on a foam surface. Gait assessment will be conducted as participants will walk a distance with a minimum of 25 steps under four conditions: (1) habitual over ground normal walk (preferred speed), (2) fast over ground, (3) habitual over ground normal walk with horizontal head turns and (4) habitual over ground normal walk with vertical head turns.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	Montreal Cognitive Assessment (MoCA) Tool	The Montreal Cognitive Assessment (MoCA) Tool is a rapid screening tool for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. It has been recommended that a cut-off scores of 23/30 be used to identify multi-domain cognitive impairment. This is the first test that will be completed. Persons with scores <23/30 will not be included in the study and will be referred back to the clinical team for further assessment and onward referral as required.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	Hospital Anxiety and Depression Scale (HADS)	The HADS, a 14-item scale which assesses non-somatic anxiety (HAD-A) and depression (HAD-D) symptoms, will also be completed. Scores range from 0-21 for each subscale with a score =8 proposed for the identification of caseness, for both depression and anxiety.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).
Secondary	Vertigo Symptom Scale (VSS)	The VSS is used to assess the frequency and severity of common vestibular (VSS-V; e.g. vertigo, imbalance) and autonomic/somatic (VSS-A; e.g. heart pounding, heavy feeling in the arms or legs) symptoms. Normalised scores range from 0-4, with higher scores indicating a higher (i.e. worse) level of symptoms.	Assessment of the change in this outcome will be performed at baseline (week 0) and end of treatment (week 10).